tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Acadia Pharmaceuticals sees FY23 NUPLAZID net sales $537.5M-$545M

Sees FY23 R&D expense $340M-$350M. Sees FY23 SG&A expense $390M-$400M.

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ACAD:

Disclaimer & DisclosureReport an Issue

1